Vodobatinib | 1388803-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Vodobatinib
• 英文别名: 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide
• CAS: 1388803-90-4
• 化学式: C₂₇H₂₀ClN₃O₂
• 分子量: 453.9
• InChiKey: ZQOBVMHBVWNVBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-methyl-3-[(quinolin-3-yl)ethynyl]benzoic acid 、 2-chloro-6-methylbenzohydrazide 在 2-chloro-6-methylbenzohydrazide 作用下， 生成 Vodobatinib
  参考文献：
  名称：

  [EN] DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS
  [FR] INHIBITEURS DE TYROSINE KINASE CONTENANT UN DIARYLACÉTYLÈNE HYDRAZIDE

  摘要：

  本发明涉及一种新型二芳基乙炔肼化合物，其化学式为（I）或其药学上可接受的盐，作为酪氨酸激酶抑制剂，其制备过程以及化合物（I）在制备用于治疗温血动物酪氨酸激酶相关疾病的药物组合物中的用途。

  公开号：

  WO2012098416A1

文献信息

• DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS
  申请人：Sengupta Prabal

  公开号：US20130296557A1

  公开（公告）日：2013-11-07

  The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animals

  本发明涉及一种新颖的二芳基乙炔基腙化合物，其化学式为(I)，或其药学上可接受的盐，作为酪氨酸激酶抑制剂，其制备过程，以及将化合物(I)用于制备与温血动物的酪氨酸激酶相关疾病的治疗药物组合物。
• COMPOUNDS FOR THE TREATMENT OF COVID-19
  申请人：Dompe' Farmaceutici S.P.A.

  公开号：EP3875078A1

  公开（公告）日：2021-09-08

  The present invention relates to compounds that are able to inhibt 3CL protease of COVID-19 virus, SARS-Cov-2

  本发明涉及能够抑制 COVID-19 病毒、SARS-Cov-2 病毒的 3CL 蛋白酶的化合物。
• Treatment of Parkinson's disease
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

  公开号：US10849887B2

  公开（公告）日：2020-12-01

  The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.

  本发明涉及一种治疗或预防受试者帕金森病的方法，包括给药式 I 的化合物 其中，R1 为-NHC(O) C3-6 环烷基，R2 为氢； 或 R1 和 R2 与它们所连接的碳原子一起形成一个六分子芳环，其中该环被一个或多个选自氢、卤素和 C1-6 烷基的基团取代； R3 和 R4 独立地选自氢、卤素、C1-3 烷基、OC1-3 烷基、NO2、SC1-3 烷基、C1-3 卤代烷基、OC1-3 卤代烷基和 SC1-3 卤代烷基组成的基团；或其药学上可接受的盐。
• Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

  公开号：US11351123B2

  公开（公告）日：2022-06-07

  An oral solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

  一种口服固体制剂，包含式 I 化合物与可熔聚合物载体的混合物；以及可选的药学上可接受的赋形剂，其中混合物为无定形分散体。
• TREATMENT OF PARKINSON'S DISEASE
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

  公开号：US20190275017A1

  公开（公告）日：2019-09-12

  The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R 1 is —NHC(O) C 3-6 cycloalkyl and R 2 is hydrogen; or R 1 and R 2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C 1-6 alkyl; R 3 and R 4 are independently selected from group comprising hydrogen, halogen, C 1-3 alkyl, OC 1-3 alkyl, NO 2 , SC 1-3 , alkyl, C 1-3 , haloalkyl, OC 1-3 haloalkyl, and SC 1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.